Last reviewed · How we verify

Asthma Controller Therapies

Sanofi · Phase 3 active Small molecule

Asthma controller therapies work by reducing airway inflammation and preventing asthma symptoms through various mechanisms including corticosteroid action, leukotriene modulation, or biologic targeting of inflammatory pathways.

Asthma controller therapies work by reducing airway inflammation and preventing asthma symptoms through various mechanisms including corticosteroid action, leukotriene modulation, or biologic targeting of inflammatory pathways. Used for Asthma maintenance therapy.

At a glance

Generic nameAsthma Controller Therapies
SponsorSanofi
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

Asthma controller therapies encompass multiple drug classes designed for long-term maintenance treatment rather than acute symptom relief. These include inhaled corticosteroids that suppress airway inflammation, long-acting beta-2 agonists that relax airway smooth muscle, leukotriene receptor antagonists that block inflammatory mediators, and biologic agents targeting specific immune pathways such as IgE or IL-5. Sanofi's Phase 3 asthma controller program likely involves one or more of these mechanisms to reduce exacerbations and improve lung function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: